Compare Dollar Tree, Inc. (DLTR) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar Tree, Inc. vs Summit Therapeutics Inc — how do they compare? Dollar Tree, Inc. trades at $128.6 (market cap $24.61B), while Summit Therapeutics Inc trades at $15.09 (market cap $12.06B). The key difference: Dollar Tree, Inc. is far larger — about 2× Summit Therapeutics Inc's market cap, and Dollar Tree, Inc. is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| DLTR | SMMT | |
|---|---|---|
Market Cap | $24.61B | $12.06B |
Sector | Health | Health |
52-Week High | $141.21 | $26.98 |
52-Week Low | $85.04 | $12.55 |
Enterprise Value | $31.20B | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar Tree (DLTR) trades at $128.85, down 0.4% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue for 2025 was $17.58 billion, but net income showed a loss of $3.03 billion due to tax impacts, while operating cash flow improved to $2.86 billion. A $2.5 billion share repurchase authorization was announced in July 2026, signaling confidence.
The outlook is mixed: analyst consensus is a Buy with a $126.69 price target, near the current price, but risks include margin pressures from tariffs and volatile profitability. Upside potential exists from cost controls and consumer demand for value, yet investors should monitor Q2 earnings and competitive dynamics closely.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
